A risk model of gene signatures for predicting platinum response and survival in ovarian cancer

Chen, Siyu; Wu, Yong; Wang, Simin; Wu, Jiawen; Wu, Xiaohua; Zheng, Zhong

doi:10.1186/s13048-022-00969-3

Cited by 17 publications

(13 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, SLC5A1, which was one of the 16 related up-regulated genes in CS group in our study, facilitates glucose transport (Mueckler and Thorens, 2013). A risk model found that SLC5A1 is one of the three hub genes that related to cisplatin therapy response in ovarian cancer (Chen et al, 2022). Several studies have also proved that an increased glycolysis rate can enhance the sensitivity to chemotherapy.…”

Section: Discussionsupporting

confidence: 57%

Increased response to TPF chemotherapy promotes immune escape in hypopharyngeal squamous cell carcinoma

Li²,

Tian³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: There is an urgent need to identify which patients would benefit from TPF chemotherapy in hypopharyngeal squamous cell carcinoma (HPSCC) and to explore new combinations to improve the treatment effect.Materials and methods: Gene-expression profiles in 15 TPF-sensitive patients were compared to 13 resistant patients. Immunohistochemistry (IHC) was performed to detect CD8+ T cells in 28 samples. Patient-Derived Tumor Xenograft (PDX) model and IHC were used to verify markers that optimize treatment for HPSCC.Results: Through RNA sequencing 188 genes were up-regulated in TPF chemotherapy-resistant (CR) tissues were involved in T cell activation, while 60 down-regulated genes were involved in glycolysis. Gene set enrichment analysis (GSEA) showed that chemotherapy-sensitive (CS) group upregulation of the pathways of glycolysis, while immune response was downregulated. CIBERSORT, MCP-counter, and IHC proved that most immune cells including CD8+ T cells in the CR significantly higher than that in CS group. Among the 16 up-regulated genes in CS had close associations, the most significant negative correlation between the gene level and CD8+ T cells existed in SEC61G. SEC61G was related to glycolysis, which was transcriptionally regulated by E2F1, and participated in antigen degradation through ubiquitin-dependent protein catabolic process. Palbociclib, combined with Cetuximab decreased the tumor burden and significantly suppressed the expression of E2F1 and SEC61G while activating MHC-I in PDX model.Conclusion: Enhanced glycolysis promoted immune escape, but increased response to TPF chemotherapy. SEC61G was the center of the molecular network and targeting the E2F1/SEC61G pathway increased the expression level of MHC-I.

show abstract

Section: Discussionsupporting

confidence: 57%

Increased response to TPF chemotherapy promotes immune escape in hypopharyngeal squamous cell carcinoma

Li²,

Tian³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Previous approaches attempting to predict response to platinum-base d chemotherapy 28,29 and doxorubicin 30,31 have been developed based on gene expression signatures for specific tumour types. Gene expression-based classifiers are challenging to implement in the clinic as clinical samples are often a mix of tumour, immune and stromal cells with variable gene expression programs.…”

Section: Discussionmentioning

confidence: 99%

Predicting response to cytotoxic chemotherapy

Madrid-Márquez¹,

Thompson²,

Vias

et al. 2023

Preprint

View full text Add to dashboard Cite

Cytotoxic chemotherapies have been a mainstay of cancer treatment for over 40 years. As they are typically administered without the use of precision biomarkers, some patients can suffer severe side effects without any benefit. The development of novel biomarkers to enable precision use of these therapies could reduce toxic side effects, improve overall response rates and reduce unnecessary healthcare expenditures. In this study we use chromosomal instability (CIN) signatures to predict a patient's response to platinum-based and doxorubicin chemotherapy. We retrospectively validated our predictor of platinum sensitivity across 41 high grade serous ovarian cancer patients. Additionally, we discovered a new biomarker for doxorubicin sensitivity based on a CIN signature related to focal DNA amplification, which we retrospectively validated across 26 patients treated with doxorubicin following platinum. We also assessed the performance of these predictors using circulating tumour DNA. As multiple CIN signature biomarkers can be quantified using a single genomic test, this represents a unified approach to guide multiple therapy choices for cytotoxic chemotherapies with the potential to shift current one-size-fits all chemotherapy treatment towards precision medicine.

show abstract

“…There are many different types of models based on clinicopathological parameters, imaging characteristics, or genetic signature to predict the stage, pathologic types, surgical outcomes, and reaction to chemotherapy, OS, or PFS, [42][43][44][45][46][47][48] but their practicability is limited partly owing to the expensive and redundant examination such as molecular diagnosis or genomic sequence. We urgently need models grounded on clinical variables with superior convenience.…”

Section: Dovepressmentioning

confidence: 99%

Development of Nomogram Models Based on Peripheral Blood Score and Clinicopathological Parameters to Predict Preoperative Advanced Stage and Prognosis for Epithelial Ovarian Cancer Patients

Bai¹,

Zhou²,

Rong³

et al. 2023

JIR

View full text Add to dashboard Cite

Nutritional and inflammatory states are crucial in cancer development. The purpose of this study is to construct a scoring system grounded on peripheral blood parameters associated with nutrition and inflammation and explore its value in stage, overall survival (OS), and progression-free survival (PFS) prediction for epithelial ovarian cancer (EOC) patients. Patients and Methods: Four hundred and fifty-three EOC patients were retrospectively identified and their clinical data and relevant peripheral blood parameters were collected. The ratio of neutrophil to lymphocyte, lymphocyte to monocyte, fibrinogen to lymphocyte, total cholesterol to lymphocyte and albumin level were calculated and dichotomized. A scoring system named peripheral blood score (PBS) was constructed. Univariate and multivariate Logistic or Cox regression analyses were used to select independent factors; these factors were then used to develop nomogram models of advanced stage and OS, PFS, respectively. The internal validation and DCA analysis were performed to evaluate models. Results: Lower PBS indicated a better prognosis and higher PBS indicated inferior. High PBS is associated with advanced stage, high CA125, serous histological type, poor differentiation, and accompanied ascites. The logistic regression showed age, CA125, and PBS were independent factors for the FIGO III-IV stage. The nomogram models for advanced FIGO stage based on these factors showed good efficiency. FIGO stage, residual disease, and PBS were independent factors affecting OS and PFS, the nomogram models composed of these factors had good performance. DCA curves revealed the models augmented net benefits. Conclusion: PBS can be a noninvasive biomarker for EOC patients' prognosis. The related nomogram models could be powerful, cost-effective tools to provide information of advanced stage, OS, and PFS for EOC patients.

show abstract

A risk model of gene signatures for predicting platinum response and survival in ovarian cancer

Cited by 17 publications

References 82 publications

Increased response to TPF chemotherapy promotes immune escape in hypopharyngeal squamous cell carcinoma

Increased response to TPF chemotherapy promotes immune escape in hypopharyngeal squamous cell carcinoma

Predicting response to cytotoxic chemotherapy

Development of Nomogram Models Based on Peripheral Blood Score and Clinicopathological Parameters to Predict Preoperative Advanced Stage and Prognosis for Epithelial Ovarian Cancer Patients

Contact Info

Product

Resources

About